Skip Navigation LinksHome > March 2012 - Volume 22 - Issue 3 > Validation of the FIGO 2009 Staging System for Carcinoma of...
International Journal of Gynecological Cancer:
doi: 10.1097/IGC.0b013e318241d994
Vulvar Cancer

Validation of the FIGO 2009 Staging System for Carcinoma of the Vulva

Tan, Jason MBBS, FRANZCOG, CGO*†; Chetty, Naven MBBS, FRANZCOG, CGO*†; Kondalsamy-Chennakesavan, Srinivas MBBS, MPH; Crandon, Alex MBBS, FRANZCOG, CGO; Garrett, Andrea MBBS, FRANZCOG, CGO*; Land, Russell MBBS, FRANZCOG, CGO*; Nascimento, Marcelo MD, FRANZCOG, CGO; Nicklin, Jim MBBS, FRANZCOG, CGO*; Perrin, Lewis MBBS, FRANZCOG, CGO; Obermair, Andreas MD, FRANZCOG, CGO*‡

Collapse Box

Abstract

Background: The previous (1988) International Federation of Gynecology and Obstetrics (FIGO) vulval cancer staging system failed in 3 important areas: (1) stage 1 and 2 disease showed similar survival; (2) stage 3 represented a most heterogeneous group of patients with a wide survival range; and (3) the number and morphology of positive nodes were not taken into account.

Objective: To compare the 1988 FIGO vulval carcinoma staging system with that of 2009 with regard to stage migration and prognostication.

Methods: Information on all patients treated for vulval cancer at the Queensland Centre for Gynecological Cancers, Australia, between 1988 to the present was obtained. Data included patients’ characteristics as well as details on histopathology, treatments, and follow-up. We recorded the original 1988 FIGO stage, reviewed all patients’ histopathology information, and restaged all patients to the 2009 FIGO staging system. Data were analyzed using the Kaplan-Meier method to compare relapse-free survival and overall survival.

Results: Data from 394 patients with primary vulval carcinoma were eligible for analysis. Patients with stage IA disease remained unchanged. Tumors formerly classified as stage II are now classified as stage IB. Therefore, FIGO 2009 stage II has become rare, with only 6 of 394 patients allocated to stage II. Stage III has been broken down into 3 substages, thus creating distinct differences in relapse-free survival and overall survival. Prognosis of patients with stage IIIC disease is remarkably poor.

Conclusion: The FIGO 2009 staging system for vulval carcinoma successfully addresses some concerns of the 1988 system. Especially, it identifies high-risk patients within the heterogeneous group of lymph node–positive patients.

Copyright © 2012 by IGCS and ESGO

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us

Twitter
twitter.com/IJGConline

For additional oncology content, visit LWW Oncology Journals on Facebook.